This week, the Spanish Society of Digestive Pathology (SEPD) became the most recent organization to announce an updated position statement on the use of biosimilars.
This week, the Spanish Society of Digestive Pathology (SEPD) became the most recent organization to announce an updated position statement on the use of biosimilars.
Published in The Spanish Journal of Gastroenterology,1 the new position statement explains the organization's current thinking on biosimilar usage, extrapolation, and switching. SEPD came to these viewpoints based on the data found by the NOR-SWITCH study, and the new views of the European Crohn’s and Colitis Organization (ECCO) on biosimilars.
SEPD’s new position holds that that:
In addition to SEPD, the American Society of Clinical Oncology (ASCO) also updated its biosimilar position statement in recent days. ASCO’s statement notes that, in terms of the safety and efficacy of biosimilars, postmarket evidence will be key to demonstrating the value of biosimilars to stakeholders. In order to make informed treatment choices, ASCO also emphasizes that prescribers should be consulted before a pharmacist substitutes an interchangeable biosimilar for a reference product. In addition, ASCO discussed the importance of healthcare stakeholders to be able to easily identify products to ensure that patients receive the correct therapy.
In order to limit patient’s out-of-pocket costs, ASCO states that, if a biosimilar is not designated as interchangeable, it could be subject to policies that cover single-source and non-preferred products. “Reasonable compensation, fair and medically appropriate coverage, and transparency of cost will serve to ensure a true value benefit to patients and society and promote access to new and innovative therapies,” notes ASCO.
Reference
1. Arguelles F, Hinojosa J, Mendoza I. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease. Published online March 12, 2018. Rev Esp Enferm Dig. doi: 10.17235/reed.2018.5456/2018.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.